Company Overview and News

SuperCharger Malaysia opens up programme to international startups

2018-04-18 themalaymailonline
The SuperCharger programme provides participating FinTech companies with market entry resources, experienced mentorship, and strategic access to industry experts, venture capitalists, and key stakeholders. — AFP picKUALA LUMPUR, April 18 — SuperCharger Malaysia is inviting applications from international FinTech companies to participate in SuperCharger Kuala Lumpur 2018 — a no-equity, 12-week programme aimed at helping promising FinTech startups to establish and scale their business in Malaysia and beyond.

Foreign insurers scramble to meet ownership cap or face wrath of Malaysia authorities

2018-02-22 scmp
International insurance companies are seeking out local partners in Malaysia ahead of a midyear deadline that will impose caps on foreigner ownership, forcing large insurers such as AIA, Prudential and Allianz to restructure their local units, according to two insurance sources.

Asian stock markets up on positive outlook

Capital inflow: Investors monitoring stock prices at a brokerage in Kuala Lumpur. On a year-to-date basis, foreign investors have bought RM10.8bil net from the open market.

Breakfast briefing: Monday, July 24

MarketWatch: Optimism is souring around small-cap stocks for some investors, with a host of factors conspiring to up-end gains that have taken them to record highs. Small-caps, which led the market's rally just after the Nov 8 election of Donald Trump as US president, are facing weak earnings forecasts, little progress on tax reform and recent outflows. - Reuters

Foreign insurers are said to plan US$2b of Malaysia deals

2017-07-21 themalaymailonline
Bank Negara has been weighing tougher enforcement of a cap on foreign ownership as it seeks to boost local participation in the industry, people familiar with the matter said in April. — Picture by Yusof Mat Isa

Bursa closes higher on last-minute buying interest

2017-07-05 themalaymailonline
KUALA LUMPUR, July 5 — Last-minute buying, mostly seen in the finance counters, pushed up the FTSE Bursa Malaysia KLCI (FBM KLCI) to close at an intra-day high today.

It’s business as usual for insurers

While good for competition and an incentive for motorists to be on their best behaviour – since the premiums they pay will rise or fall depending on their safety records – analysts said the initial impact would be minimal, as the move will be gradual to ensure market stability.

An outing to learn about money

ALLIANZ Malaysia Berhad brought 40 children on a fun visit to the Bank Negara Museum and Art Gallery in conjunction with Global Money Week 2017 celebration.

KLCI struggles to stay above 1,750 level

2017-03-28 theedgemarkets
KUALA LUMPUR (March 28): The FBM KLCI struggled to stay above the 1,750-point level in the morning session today.

KLCI pares gains, hovers above 1,750 level

2017-03-28 theedgemarkets
KUALA LUMPUR (March 28): The FBM KLCI pared some of its gains at mid-morning today but hovered above the 1,750-point level, lifted by select blue chips.

KLCI struggles to hold above 1,700 level as selling persists

2017-02-27 theedgemarkets
KUALA LUMPUR (Feb 27): The FBM KLCI struggled to to remain above the 1,700-point level at the midday break today as sellling persisted on Bursa Malaysia, despite the regional markets reversing earlier losses.

Lacklustre start for KLCI in line with region

2017-02-27 theedgemarkets
KUALA LUMPUR (Feb 27): The FBM KLCI started off on a lacklustre note this morning in line with the lukewarm investor sentiment at most regional markets.

Interesting IPO options

THE stock market sentiment may be dreary, but they say it is going to be a year of initial public offerings (IPOs).

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...